{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:18:25Z","timestamp":1793085505108,"version":"4.5.0"},"reference-count":24,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.2967\/jnumed.120.244145","type":"journal-article","created":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T01:25:18Z","timestamp":1588987518000},"page":"37-42","source":"Crossref","is-referenced-by-count":48,"title":["Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the \u0394SUV<sub>max<\/sub> Method"],"prefix":"10.2967","volume":"62","author":[{"given":"Jan","family":"Rekowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan P.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kurch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kotzerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Franzius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Weckesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Bengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Freesmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Holzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fonyuy","family":"Nyuyki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00eblle M.E.","family":"van Assema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilli","family":"Geworski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hasenclever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"J\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"2021051712154930000_62.1.37.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"2021051712154930000_62.1.37.2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2020","journal-title":"Lancet."},{"key":"2021051712154930000_62.1.37.3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","article-title":"Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial","volume":"124","author":"Schmitz","year":"2020","journal-title":"Eur J Cancer."},{"key":"2021051712154930000_62.1.37.4","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography\u2013guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol."},{"key":"2021051712154930000_62.1.37.5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00259-018-4103-3","article-title":"Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis","volume":"46","author":"Burggraaff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712154930000_62.1.37.6","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903040048"},{"key":"2021051712154930000_62.1.37.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.042093"},{"key":"2021051712154930000_62.1.37.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-327767"},{"key":"2021051712154930000_62.1.37.9","doi-asserted-by":"crossref","first-page":"e0211649","DOI":"10.1371\/journal.pone.0211649","article-title":"Comparison of therapeutic evaluation criteria in FDG-PET\/CT in patients with diffuse large-cell B-cell lymphoma: prognostic impact of tumor\/liver ratio","volume":"14","author":"Toledano","year":"2019","journal-title":"PLoS One."},{"key":"2021051712154930000_62.1.37.10","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1002\/cam4.2404","article-title":"Interim PET\/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med."},{"key":"2021051712154930000_62.1.37.11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","article-title":"Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis","volume":"85","author":"Adams","year":"2016","journal-title":"Eur J Radiol."},{"key":"2021051712154930000_62.1.37.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2435-6"},{"key":"2021051712154930000_62.1.37.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149072"},{"key":"2021051712154930000_62.1.37.14","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1200\/JCO.2018.78.9362","article-title":"Response-adapted therapy in aggressive lymphoma: not yet ready for clinical care","volume":"36","author":"Merryman","year":"2018","journal-title":"J Clin Oncol."},{"key":"2021051712154930000_62.1.37.15","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903308031"},{"key":"2021051712154930000_62.1.37.16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-018-3578-0","article-title":"Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the \u201cPositron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas\u201d (PETAL) trial","volume":"98","author":"H\u00fcttmann","year":"2019","journal-title":"Ann Hematol."},{"key":"2021051712154930000_62.1.37.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627"},{"key":"2021051712154930000_62.1.37.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00337.x"},{"key":"2021051712154930000_62.1.37.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9846"},{"key":"2021051712154930000_62.1.37.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.080556"},{"key":"2021051712154930000_62.1.37.21","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1283032"},{"key":"2021051712154930000_62.1.37.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2715-9"},{"key":"2021051712154930000_62.1.37.23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12149-016-1092-9","article-title":"Interim FDG-PET\/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)","volume":"30","author":"Annunziata","year":"2016","journal-title":"Ann Nucl Med."},{"key":"2021051712154930000_62.1.37.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210807"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.120.244145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:55:04Z","timestamp":1621284904000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.120.244145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,17]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.2967\/jnumed.120.244145"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.120.244145","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]}}}